Phathom Pharmaceuticals (PHAT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.03
- Surprise
- —
- Score today
- 6.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAT Sell at 6.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Product: VOQUEZNA
- Concentration risk — Counterparty: Takeda License
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.28
- Price target
- $7.57
- Stop
- $5.84
- Upside to target
- +20.5%
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
PHAT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $508.1M
- P/E (fwd)
- 5.8
- 52-week range
- $5.01–$18.31
- Off 52-week high
- 65.7%
- RSI (14)
- 39
- Volume vs avg
- 1.32×
- Score today
- 6.8/10